Abstract
Current evidence indicates that angiogenesis plays an important role in the pathogenesis of several malignancies, including breast cancer. Bevacizumab is a monoclonal antibody that targets the vascular endothelial growth factor (VEGF). Recent clinical data have demonstrated that the addition of bevacizumab to first-line chemotherapy improves the progression-free survival of patients with advanced breast cancer. This review presents an update on the role of bevacizumab, as well as other anti-angiogenic agents in the management of patients with breast carcinoma.
MeSH terms
-
Angiogenesis Inhibitors / pharmacokinetics
-
Angiogenesis Inhibitors / therapeutic use
-
Antibodies, Monoclonal, Humanized / pharmacokinetics
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Bevacizumab
-
Breast Neoplasms / blood supply
-
Breast Neoplasms / drug therapy*
-
Clinical Trials as Topic
-
Female
-
Half-Life
-
Humans
-
Neovascularization, Pathologic*
-
Protein Kinase Inhibitors / pharmacokinetics
-
Protein Kinase Inhibitors / therapeutic use
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Vascular Endothelial Growth Factor A / metabolism
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Protein Kinase Inhibitors
-
Vascular Endothelial Growth Factor A
-
Bevacizumab